FBR Capital Thinks Bellerophon’s Stock is Going to Recover

By George MacDonald

FBR Capital analyst Christopher James reiterated an Outperform rating on Bellerophon (NASDAQ: BLPH) on February 9. The company’s shares closed yesterday at $2.36, close to its 52-week low of $1.90.

Bellerophon has an analyst consensus of Moderate Buy.

Bellerophon`s market cap is currently $37.2M and has a P/E ratio of 3.9. The company has a book value ratio of 0.76%.

Like FBR Capital`s latest rating, based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLPH in relation to earlier this year. Most recently, in December 2015, Jonathan Peacock, a the President & CEO of BLPH bought 20,300 shares for a total of $55,728.

According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -34.6% and a 6.8% success rate. James covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc., Asterias Biotherapeutics, and Oramed Pharmaceuticals.

Bellerophon Therapeutics LLC is a clinical-stage therapeutics company developing products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary and cardiac diseases.